- Home
- PBHC vs ANL Comparison
PBHC vs ANL Comparison
Compare PBHC & ANL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PBHC
- ANL
- Stock Information
- Founded
- PBHC 1859
- ANL 2004
- Country
- PBHC United States
- ANL Cayman Islands
- Employees
- PBHC N/A
- ANL N/A
- Industry
- PBHC Major Banks
- ANL
- Sector
- PBHC Finance
- ANL
- Exchange
- PBHC Nasdaq
- ANL Nasdaq
- Market Cap
- PBHC 94.1M
- ANL 79.0M
- IPO Year
- PBHC N/A
- ANL 2023
- Fundamental
- Price
- PBHC N/A
- ANL $1.71
- Analyst Decision
- PBHC
- ANL Strong Buy
- Analyst Count
- PBHC 0
- ANL 2
- Target Price
- PBHC N/A
- ANL $9.00
- AVG Volume (30 Days)
- PBHC 2.2K
- ANL 5.0K
- Earning Date
- PBHC 05-02-2025
- ANL 04-29-2025
- Dividend Yield
- PBHC 2.62%
- ANL N/A
- EPS Growth
- PBHC N/A
- ANL N/A
- EPS
- PBHC 0.42
- ANL N/A
- Revenue
- PBHC $39,577,000.00
- ANL $5,000,000.00
- Revenue This Year
- PBHC N/A
- ANL N/A
- Revenue Next Year
- PBHC N/A
- ANL N/A
- P/E Ratio
- PBHC $36.83
- ANL N/A
- Revenue Growth
- PBHC N/A
- ANL N/A
- 52 Week Low
- PBHC $12.01
- ANL $1.71
- 52 Week High
- PBHC $19.86
- ANL $15.55
- Technical
- Relative Strength Index (RSI)
- PBHC 41.81
- ANL 35.13
- Support Level
- PBHC $15.16
- ANL $1.82
- Resistance Level
- PBHC $15.78
- ANL $2.16
- Average True Range (ATR)
- PBHC 0.47
- ANL 0.11
- MACD
- PBHC -0.06
- ANL -0.02
- Stochastic Oscillator
- PBHC 19.65
- ANL 3.92
About PBHC Pathfinder Bancorp Inc. (MD)
Pathfinder Bancorp Inc is a holding company for Pathfinder Bank. The Pathfinder Bank is a commercial bank engaged in attracting deposits from the general public and investing such deposits, together with other sources of funds, in loans secured by residential real estate, commercial real estate, small business loans, and consumer loans. The bank invests a portion of its assets in debt securities issued by the United States Government and its agencies and sponsored enterprises, state and municipal obligations, corporate debt securities, mutual funds, and equity securities. The principal source of income is interest on loans and investment securities.
About ANL Adlai Nortye Ltd.
Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.